Inhibition of Prostaglandin E 2 Synthesis in Abdominal Aortic Aneurysms
- 6 July 1999
- journal article
- other
- Published by Wolters Kluwer Health in Circulation
- Vol. 100 (1) , 48-54
- https://doi.org/10.1161/01.cir.100.1.48
Abstract
Background —There is no treatment proven to limit the growth of abdominal aortic aneurysms, in which the histological hallmarks include inflammation and medial atrophy, with apoptosis of smooth muscle cells and destruction of elastin. Methods and Results —Aneurysm biopsies were used for explant cultures, the preparation of smooth muscle cell cultures, and isolation of macrophages. Tissue macrophages stained strongly for cyclooxygenase 2. Prostaglandin E 2 (PGE 2 ) concentrations in aneurysm tissue homogenates, conditioned medium from explants, and isolated macrophages were 49±22 ng/g, 319±38 ng/mL, and 22±21 ng/mL, respectively. PGE 2 inhibited DNA synthesis and proliferation in normal aortic smooth muscle cells (IC 50 , 23.2±3.8 and 23.6±4.5 ng/mL, respectively). In smooth muscle cells derived from aneurysmal aorta, PGE 2 also caused cell death, with generation of oligonucleosomes. Conditioned medium from the mixed smooth muscle and monocyte cultures derived from explants also had potent growth-inhibitory effects, and fractionation of this medium showed that the growth-inhibitory molecule(s) coeluted with PGE 2 . In explants, indomethacin 10 μmol/L or mefenamic acid 10 μmol/L abolished PGE 2 secretion and significantly reduced IL-1β and IL-6 secretion. In a separate case-control study, the expansion of abdominal aortic aneurysms was compared in 15 patients taking nonsteroidal anti-inflammatory drugs and 63 control subjects; median growth rates were 1.5 and 3.2 mm/y, respectively, P =0.001. Conclusions —The adverse effects of PGE 2 on aortic smooth muscle cell viability and cytokine secretion in vitro and the apparent effect of anti-inflammatory drugs to lower aneurysm growth rates suggest that selective inhibition of PGE 2 synthesis could be an effective treatment to curtail aneurysm expansion.Keywords
This publication has 15 references indexed in Scilit:
- Mortality results for randomised controlled trial of early elective surgery or ultrasonographic surveillance for small abdominal aortic aneurysmsThe Lancet, 1998
- Cyclooxygenase-1 and Cyclooxygenase-2 Selectivity of Widely Used Nonsteroidal Anti-Inflammatory DrugsThe American Journal of Medicine, 1998
- Production and localization of 92-kilodalton gelatinase in abdominal aortic aneurysms. An elastolytic metalloproteinase expressed by aneurysm-infiltrating macrophages.Journal of Clinical Investigation, 1995
- The U.K. small aneurysm trial: Design, methods and progressEuropean Journal of Vascular and Endovascular Surgery, 1995
- Progression of Aortic Dilatation and the Benefit of Long-Term β-Adrenergic Blockade in Marfan's SyndromeNew England Journal of Medicine, 1994
- Analysis of 2- and 3-Series Prostanoids by Post-HPLC ELISAAnalytical Biochemistry, 1993
- Constitutive expression of a 92-kD gelatinase (type V collagenase) by rheumatoid synovial fibroblasts and its induction in normal human fibroblasts by inflammatory cytokines.Journal of Clinical Investigation, 1991
- Abdominal aortic aneurysm in 4237 screened patients: Prevalence, development and management over 6 yearsBritish Journal of Surgery, 1991
- OXFORD SCREENING PROGRAMME FOR ABDOMINAL AORTIC ANEURYSM IN MEN AGED 65 TO 74 YEARSThe Lancet, 1988
- Elastin degradation in abdominal aortic aneurysmsAtherosclerosis, 1987